PTEN and breast carcinoma: Our study provides additional support for these findings, and further suggests that integrated biomarkers of PIK3CA mutation and low PTEN are even stronger predictor of trastuzumab response than either one alone (Table 3), apparently reflecting their interacting roles in the biology of HER2-positive breast cancer.